Fominoben
Chemical compound
 | |
| Clinical data | |
|---|---|
| Trade names | Broncomenal, Deronyl, Finaten, Noleptan, Oleptan, Terion, Tosifar, Tussirama[1] |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID |
|
| DrugBank |
|
| ChemSpider |
|
| UNII |
|
| KEGG |
|
| ChEBI |
|
| ChEMBL |
|
| CompTox Dashboard (EPA) |
|
| ECHA InfoCard | 100.038.135  |
| Chemical and physical data | |
| Formula | C21H24ClN3O3 |
| Molar mass | 401.89 g·mol−1 |
| 3D model (JSmol) |
|
| |
InChI
| |
Fominoben is an antitussive agent of the benzanilide class, formerly marketed under the name Noleptan.[2] It binds poorly to the sigma-1 receptor, a receptor activated by many other antitussives.[3] It is reported to have respiratory stimulant activity.[4] Other research has indicated it may be an agonist at the benzodiazepine site of the GABAA receptor.[5] It was introduced in Germany in 1973, in Italy in 1979, and in Japan in 1983.[6]
Adverse effects include appetite suppression, nausea, vomiting, insomnia, irritability, and hallucinations. Rarer side effects include somnolence, dizziness, dry mouth, blurred vision, and urticaria.[7]
References
- ^ Swiss Pharmaceutial Society, ed. (January 2000). Index Nominum 2000: International Drug Directory. Taylor & Francis. p. 470. ISBN 978-3-88763-075-1.
- ^ "FOMINOBEN". NCATS Inxight: Drugs. Retrieved March 25, 2021.
- ^ Musacchio JM, Klein M (June 1988). "Dextromethorphan binding sites in the guinea pig brain". Cellular and Molecular Neurobiology. 8 (2): 149–56. doi:10.1007/BF00711241. PMID 3044591. S2CID 33844132.
- ^ Sasaki T, Sugiyama M, Sasaki H, Suzuki S, Takishima T (1985). "Effects of the antitussive fominoben (PB89) on hypoxia in chronic obstructive lung disease: comparison with dextromethorphan using a double-blind method". The Journal of International Medical Research. 13 (2): 96–101. doi:10.1177/030006058501300204. PMID 3158563. S2CID 30176251.
- ^ Crawley JN, Blumstein LK, Baldino F (January 1984). "Anxiolytic-like properties of fominoben". European Journal of Pharmacology. 97 (3–4): 277–81. doi:10.1016/0014-2999(84)90460-6. PMID 6142823.
- ^ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia. Elsevier. pp. 1705–7. ISBN 978-0-8155-1856-3.
- ^ Martín AV (2004). "Tratamiento sintomático de la tos y del resfriado común". Farmacología clínica y terapéutica médica. McGraw-Hill/Interamericana. p. 260. ISBN 9788448604271.
- v
- t
- e
- Acetylcysteine#
- Ambroxol
- Bromhexine
- Carbocisteine
- Dembrexine hydrochloride
- Domiodol
- Dornase alfa
- Eprazinone
- Erdosteine
- Letosteine
- Mannitol
- Mesna
- Neltenexine
- Sobrerol
- Stepronin
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
